HRP20100663T1 - POBOLJSANI sgp 130Fc DIMERI - Google Patents
POBOLJSANI sgp 130Fc DIMERI Download PDFInfo
- Publication number
- HRP20100663T1 HRP20100663T1 HR20100663T HRP20100663T HRP20100663T1 HR P20100663 T1 HRP20100663 T1 HR P20100663T1 HR 20100663 T HR20100663 T HR 20100663T HR P20100663 T HRP20100663 T HR P20100663T HR P20100663 T1 HRP20100663 T1 HR P20100663T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide dimer
- amino acid
- dimer according
- polypeptide
- domain
- Prior art date
Links
- 239000000539 dimer Substances 0.000 title claims abstract 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 18
- 229920001184 polypeptide Polymers 0.000 claims abstract 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 17
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 claims abstract 3
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 239000000178 monomer Substances 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001270 agonistic effect Effects 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001925 catabolic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000004400 serine Nutrition 0.000 claims 1
- 235000008521 threonine Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Polipeptidni dimer koji moze inhibirati aktivnost agonistickog kompleksa IL-6/sIL-6R i sadrzi dva monomera, gdje svaki od spomenutih monomera sadrzi (a) vanstanicni dio gp130 molekule ili (b) varijantu ili fragment spomenutog vanstanicnog dijela koji moze inhibirati aktivnost agonistickog kompleksa IL-6/sIL-6R, fuzioniran s Fc domenom IgG1 proteina i gdje je najmanje jedan aminokiselinski ostatak Leu235 zglobne regije Fc domene zamijenjen najmanje jednim hidrofilnim aminokiselinskim ostatkom. Patent sadrzi jos 16 patentnih zahtjeva.
Claims (17)
1. Polipeptidni dimer koji može inhibirati aktivnost agonističkog kompleksa IL-6/sIL-6R i sadrži dva monomera, gdje svaki od spomenutih monomera sadrži (a) vanstanični dio gp130 molekule ili (b) varijantu ili fragment spomenutog vanstaničnog dijela koji može inhibirati aktivnost agonističkog kompleksa IL-6/sIL-6R, fuzioniran s Fc domenom IgG1 proteina i gdje je najmanje jedan aminokiselinski ostatak Leu235 zglobne regije Fc domene zamijenjen najmanje jednim hidrofilnim aminokiselinskim ostatkom.
2. Polipeptidni dimer prema patentnom zahtjevu 1, naznačen time što je hidrofilni aminokiselinski ostatak Glu ili Asp.
3. Polipeptidni dimer prema patentnom zahtjevu 1 ili 2, naznačen time što je, dodatno, aminokiselinski ostatak Leu234 zglobne regije zamijenjen sa Phe ili Ala.
4. Polipeptidni dimer prema patentnom zahtjevu 3, naznačen time što su aminokiselinski ostaci Leu234 i/ili Gly237 zglobne regije zamijenjeni sa aminokiselinskim ostatkom Ala.
5. Polipeptidni dimer prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što zglobna regija sadrži motiv aminokiselinske sekvence Ala234-Glu235-Gly236-Ala237 umjesto Leu234-Leu235-Gly236-Gly237.
6. Polipeptidni dimer prema patentnom zahtjevu 5, naznačen time što zglobna regija sadrži aminokiselinsku sekvencu Asp221-Lys222-Thr223-His224-Thr225-Cys226-Pr227-Pro228-Cys229-Pro230-Ala231-Pro232-Glu233-Ala234-Glu235-Gly236-Ala237-Pro238-Ser239-Val240.
7. Polipeptidni dimer prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što je topljiva gp130 molekula ili njena varijanta direktno fuzionirana sa zglobnom regijom Fc domene IgG1 proteina ili preko fleksibilne polipeptidne poveznice.
8. Polipeptidni dimer prema patentnom zahtjevu 7, naznačen time što, poveznica je poveznica koja sadrži 2 do 50 aminokiselinskih ostataka nezavisno izabranih iz grupe koja se sastoji od glicina, serina, asparagina, treonina i alanina.
9. Polipeptidni dimer prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time što je jedno ili više N-glikolizacijskih mjesta umetnuto između topljive gp130 molekule ili njegove varijante ili fragmenta i Fc domene.
10. Polipeptidni dimer prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što su monomeri međusobno vezani preko jednostavne kovalentne veze, fleksibilne peptidne poveznice ili jednog ili više disulfidnih mostova.
11. Polipeptidni dimer prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što je najmanje jedan od monomera spomenutog dimera PEG-iliran.
12. Polinukleotid koji kodira monomer polipeptidnog dimera prema bilo kojem od patentnih zahtjeva 1 do 10.
13. Ekspresijski vektor koji sadrži polinukleotid prema patentnom zahtjevu 12.
14. Stanica domaćin koja sadrži ekspresijski vektor prema patentnom zahtjevu 13.
15. Postupak za proizvodnju polipeptidnog dimera prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što obuhvaća kultiviranje stanice domaćina prema patentnom zahtjevu 14 i dobivanje monomera ili dimera iz spomenute stanice domaćina ili kulture.
16. Farmaceutska smjesa koja sadrži polipeptidni dimer kao što je definiran u bilo kojem od patentnih zahtjeva 1 do 11.
17. Uporaba polipeptidnog dimera kao što je definiran u bilo kojem od patentnih zahtjeva 1 do 11 za pripremu farmaceutskih smjesa za liječenje i/ili prevenciju resorpcije kostiju, hiperkalcemije, kaheksije, tumora ili druge vrste raka, autoimune bolesti, upalne ili atopične bolesti, infekcije, endokrinološkog poremećaja ili metaboličke ili kataboličke bolesti.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06013668A EP1873166B1 (en) | 2006-06-30 | 2006-06-30 | Improved sgp 130Fc dimers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100663T1 true HRP20100663T1 (hr) | 2011-01-31 |
Family
ID=37654867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100663T HRP20100663T1 (hr) | 2006-06-30 | 2010-12-01 | POBOLJSANI sgp 130Fc DIMERI |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8895012B2 (hr) |
| EP (1) | EP1873166B1 (hr) |
| JP (1) | JP5417171B2 (hr) |
| KR (1) | KR101474817B1 (hr) |
| CN (1) | CN101484472B (hr) |
| AT (1) | ATE480568T1 (hr) |
| AU (1) | AU2007263939B2 (hr) |
| BR (1) | BRPI0713063B8 (hr) |
| CA (1) | CA2656440C (hr) |
| CY (1) | CY1110973T1 (hr) |
| DE (1) | DE602006016765D1 (hr) |
| DK (1) | DK1873166T3 (hr) |
| EA (1) | EA015620B1 (hr) |
| ES (1) | ES2352561T3 (hr) |
| HR (1) | HRP20100663T1 (hr) |
| PL (1) | PL1873166T3 (hr) |
| PT (1) | PT1873166E (hr) |
| RS (1) | RS51544B (hr) |
| SI (1) | SI1873166T1 (hr) |
| UA (1) | UA95636C2 (hr) |
| WO (1) | WO2008000516A2 (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE480568T1 (de) | 2006-06-30 | 2010-09-15 | Conaris Res Inst Ag | Verbesserte sgp 130fc dimere |
| CA2690825C (en) | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| EP2050759A1 (en) * | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Soluble gp 130 muteins with improved binding activity |
| KR20140020228A (ko) * | 2010-09-21 | 2014-02-18 | 알토 바이오사이언스 코포레이션 | 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| EP3139660B1 (en) * | 2013-09-20 | 2021-01-20 | Intel Corporation | Ap location query |
| EP3673915A1 (en) | 2014-06-30 | 2020-07-01 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| MA41116A (fr) * | 2014-12-01 | 2017-10-10 | Ferring Bv | Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif |
| DK3226888T3 (da) * | 2014-12-01 | 2021-07-12 | Ferring Bv | Administration af en selektiv inhibitor af il-6-trans-signalering |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| EP3455241B1 (en) | 2016-05-11 | 2022-02-23 | Cytiva BioProcess R&D AB | Method of cleaning and/or sanitizing a separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3529263A4 (en) | 2016-10-21 | 2020-07-08 | Altor BioScience Corporation | MULTIMERIC MOLECULES BASED ON IL-15 |
| CN108593912A (zh) * | 2018-04-09 | 2018-09-28 | 北京大学深圳研究生院 | 一种可溶性cd38浓度的检测方法 |
| CN108318689A (zh) * | 2018-04-09 | 2018-07-24 | 北京大学深圳研究生院 | 一种多发性骨髓瘤的诊断方法 |
| BR112022025166A2 (pt) | 2020-06-10 | 2022-12-27 | Ferring Bv | Composto farmacêutico para o tratamento de doença cardiovascular aterosclerótica |
| WO2022139580A1 (en) | 2020-12-22 | 2022-06-30 | Ferring B.V. | Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases |
| CN118043639A (zh) * | 2021-09-01 | 2024-05-14 | 泰利斯制药(创新)有限公司 | 聚集体分离方法 |
| WO2024011946A1 (en) * | 2022-07-12 | 2024-01-18 | I-Mab Biopharma (Hangzhou) Co., Ltd | Polypeptide dimers for the treatment of systemic sclerosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
| PL199659B1 (pl) * | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| DE19941897B4 (de) | 1999-09-02 | 2006-06-14 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen |
| ES2269366T3 (es) * | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
| DE60037648T2 (de) * | 2000-04-21 | 2010-06-17 | Conaris Research Institute Ag | Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten |
| KR20030097876A (ko) | 2001-05-21 | 2003-12-31 | 넥타르 테라퓨틱스 | 화학적으로 개질된 인슐린의 폐 투여 |
| US7507412B2 (en) * | 2001-07-18 | 2009-03-24 | Merck Patent Gmbh | Glycoprotein VI fusion proteins |
| AU2002356511A1 (en) * | 2001-07-30 | 2003-04-01 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| CA2526169A1 (en) * | 2003-06-12 | 2004-12-23 | Eli Lilly And Company | Fusion proteins |
| EP1491554A1 (en) | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGylated soluble gp130-dimers useful as a medicament |
| KR20060124656A (ko) * | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질 |
| PT1630232E (pt) | 2004-08-27 | 2008-10-02 | Conaris Res Inst Ag | Sequências de nucleótidos optimizadas que codificam sgp130 |
| EP1801121A1 (en) | 2005-12-23 | 2007-06-27 | CONARIS research institute AG | Soluble gp130 molecule variants useful as a medicament |
| ATE480568T1 (de) | 2006-06-30 | 2010-09-15 | Conaris Res Inst Ag | Verbesserte sgp 130fc dimere |
-
2006
- 2006-06-30 AT AT06013668T patent/ATE480568T1/de active
- 2006-06-30 DK DK06013668.6T patent/DK1873166T3/da active
- 2006-06-30 PT PT06013668T patent/PT1873166E/pt unknown
- 2006-06-30 ES ES06013668T patent/ES2352561T3/es active Active
- 2006-06-30 EP EP06013668A patent/EP1873166B1/en active Active
- 2006-06-30 DE DE602006016765T patent/DE602006016765D1/de active Active
- 2006-06-30 RS RSP-2010/0506A patent/RS51544B/en unknown
- 2006-06-30 SI SI200630827T patent/SI1873166T1/sl unknown
- 2006-06-30 PL PL06013668T patent/PL1873166T3/pl unknown
-
2007
- 2007-06-29 BR BRPI0713063A patent/BRPI0713063B8/pt active IP Right Grant
- 2007-06-29 CA CA2656440A patent/CA2656440C/en active Active
- 2007-06-29 AU AU2007263939A patent/AU2007263939B2/en active Active
- 2007-06-29 KR KR1020097001634A patent/KR101474817B1/ko active IP Right Grant
- 2007-06-29 CN CN2007800248791A patent/CN101484472B/zh active Active
- 2007-06-29 JP JP2009517012A patent/JP5417171B2/ja active Active
- 2007-06-29 EA EA200802396A patent/EA015620B1/ru not_active IP Right Cessation
- 2007-06-29 UA UAA200814839A patent/UA95636C2/ru unknown
- 2007-06-29 WO PCT/EP2007/005812 patent/WO2008000516A2/en active Application Filing
- 2007-06-29 US US12/307,003 patent/US8895012B2/en active Active
-
2010
- 2010-12-01 HR HR20100663T patent/HRP20100663T1/hr unknown
- 2010-12-08 CY CY20101101130T patent/CY1110973T1/el unknown
-
2013
- 2013-12-17 US US14/109,466 patent/US9034817B2/en active Active
-
2015
- 2015-04-17 US US14/689,635 patent/US9573989B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100663T1 (hr) | POBOLJSANI sgp 130Fc DIMERI | |
| HRP20200503T1 (hr) | Fuzijski proteini | |
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| JP6947642B2 (ja) | 抗がん性融合ポリペプチド | |
| JP2019507589A5 (hr) | ||
| PE20091405A1 (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| JP2014524908A5 (hr) | ||
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| MX2011009810A (es) | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. | |
| RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
| WO2004069876A3 (en) | Trimeric polypeptide construct to induce an enduring t cell response | |
| HRP20041108B1 (hr) | Peptidi povezani sa tumorom koji se vežu na mhc molekule | |
| EP3892632A1 (en) | Modified product of fc domain of antibody | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| Sulochana et al. | Developing antiangiogenic peptide drugs for angiogenesis-related diseases | |
| ATE517118T1 (de) | Bis-met-histone | |
| KR20230061392A (ko) | 수용체 쌍형성과 관련된 조성물 및 방법 | |
| IL106271A (en) | Ligand to TNF 75P receptor and its preparation | |
| BRPI0517362A (pt) | polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, anticorpo, métodos in vitro para diagnosticar uma doença em um paciente, composição farmacêutica, composição de vacina, uso de um polipeptìdeo, proteina de fusão, e, método para produção de proteìna | |
| ATE516302T1 (de) | Lösliche gp130-muteine mit verbesserter bindungsaktivität | |
| EP2948164A1 (en) | Placenta growth factor in treating duchenne muscular dystrophy | |
| WO2020095922A1 (ja) | ペプチドの血中動態改善方法 |